Document Detail


Emerging anticoagulants.
MedLine Citation:
PMID:  21352068     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Thromboembolic disease encompasses a spectrum of conditions extending from deep vein thrombosis to stroke and myocardial infarction. The current anticoagulation therapy is cumbersome and characterized by several important drawbacks.
AREAS COVERED: Existing treatments and latest breakthroughs on emerging anticoagulants are presented. Oral and parenteral novel anticoagulants are being developed and tested for efficacy and safety and results are being published regularly. The introduction of novel anticoagulants marks a new era in the management of anticoagulated patients. It is important for the healthcare provider to understand the benefits and risks of the armamentarium of anticoagulants that will be available in the very near future. The critical conclusions drawn will help the reader look past what is the most highlighted feature of the new anticoagulantion era: the non-necessity for monitoring.
EXPERT OPINION: Currently, novel anticoagulants seem to lack the indefinable 'charm' of weakness. However, important questions remain unanswered and will require in-depth evaluations.
Authors:
Gentian Denas; Vittorio Pengo
Related Documents :
11093098 - A new framework for echocardiographic assessment of left ventricular mechanics: sensiti...
6375498 - Reevaluation of digitalis efficacy. new light on an old leaf.
2048568 - Circulatory abnormalities and compensatory mechanisms in heart failure.
1984898 - Diltiazem increases late-onset congestive heart failure in postinfarction patients with...
7884098 - Left ventricular mass increases during cardiac allograft vascular rejection.
24182508 - Mitral stenosis reversed by medical treatment for heart failure.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on emerging drugs     Volume:  16     ISSN:  1744-7623     ISO Abbreviation:  Expert Opin Emerg Drugs     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-02-28     Completed Date:  2011-07-11     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101135662     Medline TA:  Expert Opin Emerg Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  31-44     Citation Subset:  IM    
Affiliation:
University of Padua School of Medicine, Clinical Cardiology, Thrombosis Center, Department of Cardiothoracic and Vascular Sciences, Via Giustiniani 2, 35128 Padua, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / administration & dosage,  adverse effects,  therapeutic use*
Clinical Trials as Topic
Drug Discovery* / methods
Humans
Thromboembolism / blood,  drug therapy*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anticoagulants

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Emerging antiarrhythmic agents: a personal view from the Far East.
Next Document:  Emerging drugs for Waldenström's macroglobulinemia.